Skip to main content

Table 1 Comparison of clinical variables between SLE patients and healthy controls

From: Assessment of serum macrophage migration inhibitory factor (MIF), adiponectin, and other adipokines as potential markers of proteinuria and renal dysfunction in lupus nephritis: a cross-sectional study

Variable SLE
n = 196
Healthy Controls
n = 52
p
Age (years) a 45 (18–73) 47 (22–54) 0.87
Gender b 196 (100) 52 (100)
Mexican-Mestizo b 196 (100) 52 (100)
BMI (kg/m2) a 27.3 (17.7–40.0) 27.9 (18.4–47.3) 0.86
SLE duration (years) a 8.3 (2–28)
C3 fraction complement (mg/dL) a 142.0 (42.0–252.0)
C4 fraction complement (mg/dL) a 31 (6.6–71.7)
Positive anti-dsDNA b 55 (28.1)
SLEDAI (score) a 2 (0–12)
rSLEDAI (score) a 0 (0–12)
 - Renal-SLE patients b 43 (21.9)
SLICC/ACR (score) a 1 (0–5)
MEX-SLEDAI (score) a 1 (0–10)
Glucocorticoids b 196 (100)
 - Prednisone > 10 mg/day b 60 (30.6)
Immunosuppressive drugs b 145 (74.0)
 - Azathioprine users b 91 (46.4)
 - Cyclophosphamide users b 13 (6.6)
 - Mycophenolate users b 56 (28.5)
Other drugs (Methotrexate) b 27 (13.8)   
  1. a Data expressed as medians and ranges (minimum and maximum value). b Data provided in frequencies (percentages). SLE Systemic Lupus Erythematosus, SLEDAI original SLE Disease Activity Index, high score indicates higher disease activity, SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of Rheumatology, rSLEDAI Renal-SLEDAI score (includes proteinuria greater than 0.5 g in 24 h, persistent hematuria, leucocytes on urine or urine casts -granulocytes or erythrocytes-), higher score indicates high renal disease activity. MEX-SLEDAI: Version of SLEDAI validated in Mexico. Comparisons between proportions: Chi- square (or Fisher exact test if required). Comparisons between quantitative variables: Mann-Whitney U test